<code id='4316BF6381'></code><style id='4316BF6381'></style>
    • <acronym id='4316BF6381'></acronym>
      <center id='4316BF6381'><center id='4316BF6381'><tfoot id='4316BF6381'></tfoot></center><abbr id='4316BF6381'><dir id='4316BF6381'><tfoot id='4316BF6381'></tfoot><noframes id='4316BF6381'>

    • <optgroup id='4316BF6381'><strike id='4316BF6381'><sup id='4316BF6381'></sup></strike><code id='4316BF6381'></code></optgroup>
        1. <b id='4316BF6381'><label id='4316BF6381'><select id='4316BF6381'><dt id='4316BF6381'><span id='4316BF6381'></span></dt></select></label></b><u id='4316BF6381'></u>
          <i id='4316BF6381'><strike id='4316BF6381'><tt id='4316BF6381'><pre id='4316BF6381'></pre></tt></strike></i>

          hotspot

          hotspot

          author:hotspot    Page View:3
          Cosmetics
          Alberto Pellaschiar/AP

          WASHINGTON — For those already felled by fumes from the Brazilian Blowout, it might be small consolation, but lawmakers are pushing ahead with a campaign for better oversight of the beauty business.

          Despite its booming growth, the cosmetics industry in the US has been virtually unregulated. The Food, Drug, and Cosmetic Act, adopted in 1938, essentially allowed personal care product companies to self-police.

          advertisement

          But rising public concern over bad reactions to makeup, hair dyes, and fragrances, as well as evidence of long-term health risks from some of their chemical contents, has led lawmakers to try to toughen the regulatory framework for the $60 billion enhancement industry.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio
          The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

          RubyWallauforSTATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Kidney transplant patients stopped immunosuppressants in trial

          BRENDANSMIALOWSKI/AFP/GettyImagesKidneytransplantsarethemostcommonorgantransplantprocedureintheU.S.,